| Gene Symbol | PLD4 |
|---|---|
| Full Name | Phospholipase D4 |
| Chromosomal Location | 22q12.1 |
| NCBI Gene ID | 122809 |
| OMIM | 614786 |
| Ensembl ID | ENSG00000138184 |
| UniProt ID | Q96BZ4 |
| Associated Diseases | Autoimmune disorders, Cerebellar ataxia, Inflammatory bowel disease |
PLD4 (Phospholipase D4) encodes a member of the phospholipase D family that possesses both phospholipase D enzymatic activity and 5'→3' exonuclease capability. Unlike classical phospholipases involved in lipid signaling, PLD4 performs unique functions in innate immunity through its ability to degrade nucleic acids and regulate Toll-like receptor (TLR) signaling pathways[1]. The gene is expressed predominantly in immune cells and is increasingly recognized for its role in preventing aberrant inflammatory responses.
PLD4 functions as a phospholipase D that catalyzes the hydrolysis of phospholipids to generate phosphatidic acid. A distinctive feature of PLD4 is its specificity for synthesizing (S,S)-bis(monoacylglycero)phosphate (BMP), also known as lysobisphosphatidic acid (LBPA), a critical phospholipid in lysosomal lipid degradation[2]. BMP is essential for proper lysosomal function and autophagy, and PLD4 represents the primary enzymatic source of this lipid species in mammals.
PLD4 possesses 5'→3' exonuclease activity that degrades single-stranded DNA (ssDNA) and RNA. This activity is crucial for its role in:
While PLD4 is primarily studied in the context of innate immunity and autoinflammatory disorders, emerging evidence suggests connections to neurodegenerative processes:
PLD4-regulated TLR signaling pathways are directly relevant to neuroinflammation in Alzheimer's disease (AD) and Parkinson's disease (PD):
Polymorphisms in PLD4 have been associated with autoimmune conditions that show comorbidity with neurodegenerative diseases:
PLD4 expression in the brain is primarily localized to:
Expression is generally low in neurons under normal conditions but increases in response to neuroinflammatory stimuli[5].
PLD4 interacts with several proteins relevant to its enzymatic functions:
Modulating PLD4 activity represents a potential therapeutic strategy:
PLD4-deficient mice develop spontaneous autoinflammatory disease characterized by:
These models demonstrate the critical role of PLD4 in maintaining immune homeostasis.
Pathogenic variants in PLD4 have been associated with:
PLD4 represents a unique intersection of phospholipid metabolism, nucleic acid degradation, and innate immunity. While not traditionally considered a neurodegeneration gene, its role in regulating neuroinflammatory pathways through TLR signaling places it in the broader context of neurodegenerative disease mechanisms. Further research into PLD4 function may reveal therapeutic targets for modulating neuroinflammation in AD, PD, and related disorders.
Gondard E, et al. Phospholipase D4 regulates TLR9-mediated autoinflammatory responses. Proc Natl Acad Sci USA. 2017. ↩︎ ↩︎
Aceland M, et al. Lysosomal phospholipase D4 and lipid metabolism. J Lipid Res. 2018. ↩︎
Moriya K, et al. PLD4 regulates mitochondrial DNA clearance in macrophages. Cell Rep. 2019. ↩︎
Kotake S, et al. PLD4 polymorphisms and autoimmune disease susceptibility. J Autoimmun. 2019. ↩︎
Tanaka K, et al. PLD4 expression in the mammalian brain. Neuroscience. 2016. ↩︎
Suzuki T, et al. Inhibition of PLD4 as a therapeutic strategy for autoimmune disorders. Autoimmunity. 2020. ↩︎
Han SB, et al. PLD4 deficiency causes autoinflammatory disease in mice. Nat Immunol. 2018. ↩︎
Zhao Y, et al. PLD4 mutations in patients with cerebellar ataxia. Neurology. 2019. ↩︎